rdf:type |
|
lifeskim:mentions |
umls-concept:C0011777,
umls-concept:C0013216,
umls-concept:C0013470,
umls-concept:C0027497,
umls-concept:C0030705,
umls-concept:C0042963,
umls-concept:C0178602,
umls-concept:C0205171,
umls-concept:C0205250,
umls-concept:C0205411,
umls-concept:C0220578,
umls-concept:C0318598,
umls-concept:C0332293,
umls-concept:C1424628,
umls-concept:C1548161,
umls-concept:C2587213
|
pubmed:issue |
12
|
pubmed:dateCreated |
2009-11-11
|
pubmed:abstractText |
The aim of our study was to evaluate the efficacy of a single-dose palonosetron plus dexamethasone to control emesis in patients (pts) receiving HEC. Moreover, we evaluated the amount of their food intake (FI) in the week following therapy, in order to measure any reduction of calories consumption related to Chemotherapy-induced nausea and vomiting (CINV).
|
pubmed:language |
eng
|
pubmed:journal |
|
pubmed:citationSubset |
IM
|
pubmed:chemical |
|
pubmed:status |
MEDLINE
|
pubmed:month |
Dec
|
pubmed:issn |
1433-7339
|
pubmed:author |
|
pubmed:issnType |
Electronic
|
pubmed:volume |
17
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
1469-73
|
pubmed:meshHeading |
pubmed-meshheading:19294429-Aged,
pubmed-meshheading:19294429-Antiemetics,
pubmed-meshheading:19294429-Antineoplastic Agents,
pubmed-meshheading:19294429-Dexamethasone,
pubmed-meshheading:19294429-Drug Therapy, Combination,
pubmed-meshheading:19294429-Eating,
pubmed-meshheading:19294429-Female,
pubmed-meshheading:19294429-Humans,
pubmed-meshheading:19294429-Isoquinolines,
pubmed-meshheading:19294429-Male,
pubmed-meshheading:19294429-Middle Aged,
pubmed-meshheading:19294429-Nausea,
pubmed-meshheading:19294429-Neoplasms,
pubmed-meshheading:19294429-Prospective Studies,
pubmed-meshheading:19294429-Quinuclidines,
pubmed-meshheading:19294429-Serotonin Antagonists,
pubmed-meshheading:19294429-Vomiting
|
pubmed:year |
2009
|
pubmed:articleTitle |
Single dose of palonosetron plus dexamethasone to control nausea, vomiting and to warrant an adequate food intake in patients treated with highly emetogenic chemotherapy (HEC). Preliminary results.
|
pubmed:affiliation |
Oncology Unit, Vito Fazzi Hospital, Lecce, Italy. vitolorusso@inwind.it
|
pubmed:publicationType |
Journal Article,
Clinical Trial
|